Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer?

Prostate Cancer and Prostatic Diseases

Volumn 4, Issue 2, 2001, Pages 72-80

  Chodak, G W ^a   Kolvenbag, G J C M ^b  

^a Midwest Prostate and Urology Health Center   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Bicalutamide; Hormone responsive tumours; Non steroidal antiandrogens; Prostate cancer; Tamoxifen

Indexed keywords

ANTIANDROGEN; ANTIESTROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; ESTROGEN RECEPTOR; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; LEUPRORELIN; MEGESTEROL ACETATE; NILUTAMIDE; PLACEBO; PROGESTERONE DERIVATIVE; RALOXIFENE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG HALF LIFE; DRUG MECHANISM; EXPERIENCE; FEMALE; GYNECOMASTIA; HIGH RISK PATIENT; HORMONE RESPONSE; HOT FLUSH; HUMAN; IMPOTENCE; MALE; MULTICENTER STUDY; ORCHIECTOMY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; THROMBOEMBOLISM;

EID: 0034941886     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500518     Document Type: Article

References (144)

1. On the treatment of inoperable carcinoma of the mamma: Suggestion of a new method of treatment with illustrative cases
2. Influence of synthetic oestrogens upon advanced malignant disease
3. New synthetic agent for the induction of ovulation: Preliminary trial in women
4. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model
5. Oestrogen receptors and breast cancer response to adrenalectomy
6. Anti-oestrogen therapy for breast cancer. A trial of tamoxifen at two dose levels
7. A new antioestrogenic agent in late breast cancer: An early clinical trial
8. Abnormal 24-h mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer
9. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer
10. Studies on the oestrogen receptor in breast cancer
11. Treatment of primary breast cancer with chemotherapy and tamoxifen
12. Influence of tumour oestrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer
13. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial
14. Tamoxifen in advanced breast cancer
15. Predicting response to endocrine therapy in human breast cancer: A hypothesis
16. Predictive value of tumour oestrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene
17. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
18. Tamoxifen and fluoxymesterone in advanced breast cancer
19. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer
20. Megestrol acetate vs. tamoxifen in advanced breast cancer: Correlation of hormone receptors and response
21. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer
22. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma
23. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer
24. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer
25. Tamoxifen (nolvadex) versus adrenalectomy in metastatic breast cancer
26. Adjuvant chemotherapy, anti-oestrogen therapy and immunotherapy for stage II breast cancer
27. Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials
28. Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer
29. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer
30. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial
31. The use of endocrine therapy
32. Adjuvant hormonal chemotherapy in early breast cancer: Early results from a controlled trial
33. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo
34. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis
35. Adjuvant treatment for early breast cancer: The Ludwig breast cancer studies
36. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer
37. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have oestrogen-receptor-positive tumours
38. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
39. Polychemotherapy for early breast cancer: An overview of the randomised trials
40. Tamoxifen for early breast cancer: An overview of the randomised trials
41. The EBCTCG overview of adjuvant therapy of breast cancer. What are the implications for future studies?
42. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
43. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer
44. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and oestrogen receptor-positive tumours
45. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer
46. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma
47. Status of antioestrogen breast cancer prevention trials
48. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
49. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
50. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen
51. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
52. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen
53. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
54. Oestrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice
55. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
56. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients
57. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
58. Risk of endometrial cancer after tamoxifen treatment of breast cancer
59. A risk benefit assessment of tamoxifen therapy
60. Tamoxifen and endometrial cancer: Clearing up a controversy
61. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial
62. Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter, double-blind, randomized trials in ∼ 12,000 postmenopausal women
63. Effects of high dose raloxifene in selected patients with advanced breast carcinoma
64. Targeted antioestrogens to prevent breast cancer
65. Studies on prostatic cancer. 1. Effect of castration, of oestrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate
66. Oestrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo
67. Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate
68. The Veterans Administration Cooperative Urological Research Group studies of carcinoma of the prostate: A review
69. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies
70. Isolation of properties of the FSH and LH-releasing hormone
71. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy
72. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in the treatment of prostate cancer
73. Zoladex versus orchiectomy in the treatment of advanced prostate cancer
74. Treatment of patients with advanced cancer of the prostate: Phase II trial, Zoladex against castration; a study of the British Prostate Group
75. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
76. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of the prostate
77. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide)
78. Bone mineral density in men treated with synthetic gonadotrophin-releasing hormone agonists for prostatic carcinoma
79. Osteoporosis after orchiectomy for prostate cancer
80. Medical castration using megestrol acetate and minidose oestrogen
81. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma
82. Analysis of the androgenic activity of synthetic 'progestins' currently used for the treatment of prostate cancer
83. Progressive prostate cancer associated with the use of megestrol acetate administered for control of hot flashes
84. Ketoconazole and liarozole in the treatment of advanced prostatic cancer
85. Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate
86. Cardiovascular side effects of diethylstilbestrol, cyproteroneacetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Treatment of Cancer trials 30761 and 30762
87. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
88. Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer
89. Treatment of advanced prostate cancer, resistant to conventional therapy
90. Comparison of prostate cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or oestrogen therapy
91. Adrenal androgen blockade in relapsed prostate cancer
92. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer
93. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro
94. Antiandrogens in the treatment of prostatic cancer
95. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer
96. New hormonal treatment in cancer of the prostate: Combined administration of an LHRH agonist and an antiandrogen
97. Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate
98. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer
99. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival
100. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations
101. Combination therapy in prostate cancer
102. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
103. Casodex-mechanisms of action and opportunities for usage
104. Bicalutamide in the treatment of advanced prostatic carcinoma: A phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy
105. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer
106. Bicalutamide (Casodex) in the treatment of prostate cancer: History of clinical development
107. Maximal androgen blockade for patients with metastatic prostate cancer: Outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy
108. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial
109. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials
110. Androgen blockade in prostate cancer
111. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
112. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
113. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 y of followup
114. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
115. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease
116. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy
117. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
118. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis
119. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer
120. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer
121. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance
122. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade
123. Prostate-specific antigen levels after radical prostatectomy in patients with organ-confined and locally extensive prostate cancer
124. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation
125. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
126. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31
127. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer
128. Randomized multicenter trial on adjuvant flutamide therapy in locally advanced cancer after radical prostatectomy
129. A review of studies of hormonal adjuvant therapy in prostate cancer
130. Bicalutamide ('Casodex') 150 mg as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer
131. Chemoprevention strategies for prostate cancer: The role of 5 alpha-reductase inhibitors
132. Benign prostatic hyperplasia. Medical and minimally invasive treatment options
133. Chemoprevention of prostate cancer: The Prostate Cancer Prevention Trial
134. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels
135. Clinical utility of prostatic intraepithelial neoplasia
136. Large acinar atypical hyperplasia and carcinoma of the prostate
137. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients
138. Decrease of prostatic intraepithelial neoplasia (PIN) following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy
139. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery
140. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer
141. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer
142. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays
143. A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the Combined Hormonal Agent Trialists' Group
144. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer